SGLT2 Inhibitors Reduce CV Mortality, Heart Failure Hospitalizations in Patients With Heart Failure: Systematic Review and Meta-analysis

May 15-17, 2021; Virtual
In meta-analysis of 15 randomized, placebo-controlled clinical trials, SGLT2 inhibitors reduced risk of all-cause and CV mortality and risk of composite heart failure endpoint in key patient subgroups.
Format: Microsoft PowerPoint (.ppt)
File Size: 309 KB
Released: July 1, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Related Content

From Clinical Care Options (CCO), new data in managing heart failure from ACC 2021

Lee R. Goldberg, MD, MPH, FACC James Udelson, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: July 28, 2021 Expired: July 27, 2022

Dr. Lee R. Goldberg discusses key studies from ACC 2021 that will impact heart failure management, as reported by Clinical Care Options (CCO)

Lee R. Goldberg, MD, MPH, FACC Released: July 15, 2021

From Clinical Care Options (CCO) and Dr. James Udelson, expert commentary on new data in heart failure management from ACC 2021

James Udelson, MD Released: July 14, 2021

Latest data on empagliflozin in routine care of patients with type 2 diabetes from ACC 2021 reported by Clinical Care Options (CCO)

Released: June 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue